Gland Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Gland Pharma's recent management commentary highlights a strategic pivot towards high-value complex injectables and enhanced CDMO services, which are expected to drive revenue growth and margin expansion. The company is executing a substantial INR 2,000 crore capex program aimed at increasing capacity for vials and liposomal products, aligning with the rising demand in the global market. Analysts remain optimistic about the company's long-term growth trajectory, projecting a 20% revenue CAGR over the next four years, supported by a robust pipeline and strategic partnerships. However, potential risks include supply chain disruptions and the complexities associated with integrating new facilities. Vista's financial outlook reflects stable revenue growth and improving margins, with a fair valuation aligned with intrinsic value. The expected upside of approximately 19.6% underscores the market's constructive sentiment towards Gland Pharma. Industry dynamics, including improving pricing power and the expansion of the biopharma market, further bolster the company's position. Over the next 12-24 months, key opportunities lie in the successful execution of capacity expansions and new product launches, while watchpoints include supply chain stability and the integration of recent acquisitions
Why We Like This Stock
- Strategic pivot towards high-value complex injectables and CDMO services is expected to drive revenue growth
- Execution of a significant capex program to expand capacity aligns with rising global demand
- Management's optimistic long-term growth guidance supports a favorable market outlook
Things To Watch Out For
- Potential supply chain disruptions could impact revenue and operational efficiency
- Complexities in integrating new facilities may pose execution risks
- Dependence on high-volume US generic formulations could constrain growth in the near term
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 5,665 | 5,616 | 6,431 | 7,036 | 8,153 |
| Profit Before Tax (Cr.) | 1,132 | 1,062 | 1,489 | 1,833 | 2,064 |
| PBT Margin | 20.0% | 18.9% | 23.2% | 26.1% | 25.3% |
| Net Profit (Cr.) | 783 | 691 | 1,023 | 1,257 | 1,415 |
| Earnings Per Share | 47.5 | 41.9 | 62.0 | 76.2 | 85.8 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Elara Capital | ► Accumulate | 2,956 | 11-Aug-2026 |
| Goldman Sachs | ▼ Sell | 2,125 | 11-Aug-2026 |
| Jeffries | ▲ Buy | 3,350 | 11-Aug-2026 |
| Motilal Oswal | ▲ Buy | 3,080 | 11-Aug-2026 |
| Kotak Securities | ► Add | 2,625 | 27-Jul-2026 |
| ICICI Securities | ▲ Buy | 2,365 | 18-May-2026 |
Company Overview
Show Company Profile
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, and neurological and central nervous system; blood related, ophthalmics and otologicals, cardiac, gastro-intestinal, and hormonal products; pain, neuromuscular blocking agents, and analgesics; respiratory and pulmonology; and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier preparation, and technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.